Fulcrum Therapeutics FULC is set to give its latest quarterly earnings report on Wednesday, 2024-11-13. Here's what investors need to know before the announcement.
Analysts estimate that Fulcrum Therapeutics will report an earnings per share (EPS) of $-0.41.
The announcement from Fulcrum Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Past Earnings Performance
The company's EPS beat by $0.88 in the last quarter, leading to a 2.91% drop in the share price on the following day.
Here's a look at Fulcrum Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.01 | -0.44 | -0.43 | -0.44 |
| EPS Actual | 0.87 | -0.43 | -0.40 | -0.39 |
| Price Change % | -3.0% | 8.0% | 1.0% | -3.0% |
To track all earnings releases for Fulcrum Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
